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To get insight into the sensitivity of fluorescence microscopy for diagnostic and follow-up
sputum samples from pulmonary tuberculosis patients in clinical trials, the yield of smear
positivity – among culture positive sputum samples – encountered in diagnostic and fol-
low-up samples was retrospectively analyzed from the data available in a mycobacteriology
laboratory in India. The sensitivity of fluorescence microscopy for diagnostic and follow-up
samples respectively was found to be 94.3% and 60.7%. With these values as guidelines, the
performance of fluorescence microscopy in the treatment of multi-drug resistant tubercu-
losis under DOTS plus program remains to be monitored and studied.
 2012 Asian-African Society for Mycobacteriology. All rights reserved.Introduction
Sputum acid-fast bacilli (AFB) smear microscopy is the most
employed diagnostic tool used in the diagnosis of pulmonary
tuberculosis (PTB) all over the world [1]. It is performed either
using light microscopes or fluorescent microscopes. With the
rapid expansion of culture and drug susceptibility testing
(DST) laboratories across the globe for rapid diagnosis of
multi-drug resistant tuberculosis (MDR-TB), the performance
indicators for microscopy and culture and DST procedures in
mycobacteriology laboratories are to be monitored and the
quality of work has to be ascertained [2]. Though there are
internationally accepted consensus guidelines for ensuring
the quality of Ziehl Neelsen (ZN) sputum AFB microscopy
[3], no such guidelines have been framed for fluorescence
microscopy (FM). Recently, McCarthy et al. [2] suggested labo-
ratory performance indicators for assessing the quality of-African Society for Myco
Institute for Research in T
m (N. Selvakumar).smear and solid (Lowenstein–Jensen) culture methods in
mycobacteriology laboratories. They considered only diag-
nostic samples to define performance indicators for micros-
copy and culture and DST methods, and pointed out that
performance indicators for different types of samples (diag-
nostic, follow-up, morning, spot, direct samples, concen-
trated samples, preserved samples, transported samples,
and different samples from different extra-pulmonary TB)
could vary and are to be studied. Sufficient information is
available on the laboratory indicators of ZN microscopy for
diagnostic samples [4]. However, the information for follow-
up samples, collected from PTB patients on treatment and
follow-up, is not well documented. It is also essential to
segregate the diagnostic and follow-up samples and analyze
the various performance indicators for ZN/FM microscopy.
In the present study, an attempt was made to precisely gauge
the performance of FM in a mycobacteriology laboratory inbacteriology. All rights reserved.
uberculosis (ICMR), Mayor Sathiyamurthy Road, Chetpet, Chennai
Table 1 – Distribution of smear results against the corre-
sponding culture results.
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from PTB patients enrolled in controlled clinical trials.Smeara Cultureb Total
1+ 2+ 3+ Col
a. Diagnostic samples
1+ 34 138 71 3 246
2+ 9 81 135 0 225
3+ 0 12 47 0 59
NEG 11 17 2 2 32
Total 54 248 255 5 562
b. Follow-up samples
1+ 63 37 9 59 168
2+ 6 9 18 6 39
3+ 0 1 6 0 7
NEG 67 5 1 65 138
Total 136 52 34 130 352
a 3+: More than 100 AFB per field (200·) in at least 20 fields; 2+: 5–100
AFB per field in at least 50 fields; 1+: minimum 4 AFB/less than 5 AFB
per field in at least 50 fields.
b 3+: confluent growth; 2+: innumerable number of colonies; 1+: 20–
100 colonies; Cols: 1–19 colonies.Methods
From each of the patients admitted and followed in con-
trolled clinical trials at the National Institute for Research
in Tuberculosis, Chennai, India, four samples (two morning
and two spot samples), collected before initiating treatment,
three samples (one spot and two morning) collected at each
month during treatment, and two samples (one spot and
one morning) collected during the 24-month follow-up peri-
od after completing treatment were subjected to bacteriolog-
ical examination. A direct smear from each of the samples
was prepared and stained by auramine phenol staining
method. The smears were examined by FM (mercury vapor
lamp) as per standard operating procedures followed in the
laboratory [5]. All AFB positive smears and 20% of the nega-
tive smears were checked by a senior technologist before
reporting the smear results. All the samples were cultured
on solid LJ medium for growth of Mycobacterium tuberculosis,
after NaOH decontamination and concentration by centrifu-
gation [5]. Of the cultures isolated from each of the patients,
two among diagnostic and one among follow-up samples, if
available, were selected for DST. The smear and culture
grade of these selected cultures were recorded and main-
tained in a register in the mycobacteriology laboratory to en-
sure timely reporting of DST results to the patients. The
smear results for 562 diagnostic and 352 follow-up culture
positive samples from 281 patients were available for analy-
sis. The controlled clinical trial was approved by the Insti-
tute’s ethics committee, and individual patient’s consent
was obtained. The patients, treated with short-course regi-
mens ranging from 3 to 6 months, were followed for
24 months. The data (name of the patient, unique ID num-
ber, laboratory number, and smear and culture grade of the
culture) were entered using Microsoft Excel software, and
the sensitivity of FM was calculated against the culture as
the gold standard.Results
Table 1 shows the distribution of smear grades among
diagnostic and follow-up culture positive samples. Of
the 562 diagnostic culture positive samples, 530 (94.3%)
were smear positive. Of the 562, 503 and 59, respectively,
were high (2+ and 3+) and low (cols and 1+) grade culture
positive. Of 503 high-grade and 59 low-grade culture posi-
tive samples, 484 (96.2%) and 46 (77.9%) respectively were
smear positive. Of the 352 follow-up culture positive sam-
ples, 214 (60.7%) were smear positive. Of the 352, 86 and
266 were, respectively, high- and low-grade culture positive
samples. Of the 86 high and 266 low-grade culture positive
samples, 80 (93%) and 134 (50.3%) were positive by smear
respectively. Among all culture positive and in the low-
grade culture positive samples, the difference in smear
positivity between diagnostic and follow-up samples(94.3% vs. 60.7%) and (77.9% vs. 50.3%) attained statistical
significance as shown in Table 1.Discussion
The sensitivity of FM for diagnostic and follow-up samples
was 94.6% and 60.7% respectively. The very high sensitivity
(94.6%) in diagnostic samples, achieved in this study, could
be the result of the selective referral of PTB suspects from
the diagnostic centers in the study area. The low sensitivity
for follow-up samples (60.7%), especially in low-grade culture
positive samples (50.4%; 134/266) could be attributed to the
paucibacillary nature of samples often with damaged and dif-
ficult to stain bacilli [6]. This is evident with the observation
that 266 of 352 follow-up samples yielded low positives (less
than 20 colonies and 1+) during the follow-up period. This
provides foresight into the performance indicator for FM in
follow-up samples. However, it should also be kept in mind
that the sensitivity of FM for follow-up samples might vary
depending upon the regimen used to treat patients and in
the follow-up period; it needs further analysis of data from
different sites having different treatment regimens.
The data in the present study was collected from a spe-
cially designed culture card for each patient where only labo-
ratory numbers of presumptively culture positive samples
were recorded and maintained in the laboratory. It should
be pointed out that the Revised National Tuberculosis Control
Programme (RNTCP) recommended culture and DST register
contains information on diagnostic and follow-up samples,
and separate analysis of performance indicators for diagnos-
tic and follow-up samples is feasible [7]. In the present study,
for the first time, the smear results of culture positive diag-
nostic and follow-up samples obtained in a controlled clinical
trial were analyzed exclusively to get an insight into the
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culture positive forM. tuberculosis during the follow-up period
were not available for analysis, two positive cultures among
the diagnostic samples and one culture, isolated from each
month during treatment and the follow-up period, when
available, were included in the analysis.
Conclusion
The sensitivity of FM as a performance indicator for diagnos-
tic and follow-up samples in PTB was found to be 94.3% and
60.7% in controlled clinical trial settings, and these values
can be a guide to monitoring the quality of FM in the DOTS
plus program in different settings.
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